BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30448640)

  • 1. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
    Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
    Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
    Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
    J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
    Ara A; Love RP; Chelico L
    PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
    Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
    J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
    Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
    Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
    Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
    J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
    Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
    J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
    Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
    J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
    Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
    J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
    Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
    J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.